Genetically Modified T Cells for the Treatment of Malignant Disease | Zendy

Agnieszka Wieczorek | Zendy; Lutz Uharek | Zendy

AI Assistant Blog Pricing

Home ZAIA Blog

Open Access

Genetically Modified T Cells for the Treatment of Malignant Disease

Author(s) -

Agnieszka Wieczorek,

Lutz Uharek

Publication year - 2013

Publication title -

transfusion medicine and hemotherapy

Language(s) - English

Resource type - Journals

SCImago Journal Rank - 0.971

H-Index - 39

eISSN - 1660-3818

pISSN - 1660-3796

DOI - 10.1159/000357163

Subject(s) - malignant cells , adoptive cell transfer , disease , immunology , antigen , cell therapy , cell , cancer research , biology , computational biology , t cell , medicine , cancer , immune system , genetics , pathology

The broaden application of adoptive T-cell transfer has been constrained by the technical abilities to isolate and expand antigen-specific T cells potent to selectively kill tumor cells. With the recent progress in the design and manufacturing of cellular products, T cells used in the treatment of malignant diseases may be regarded as anticancer biopharmaceuticals. Genetical manipulation of T cells has given T cells desired specificity but also enable to tailor their activation and proliferation potential. Here, we summarize the recent developments in genetic engineering of T-cell-based biopharmaceuticals, covering criteria for their clinical application in regard to safety and efficacy.

The content you want is available to Zendy users.

Already have an account? Click here to sign in.

Having issues? You can contact us here

Accelerating Research